Forbion

Profile

Forbion is a Netherlands-based venture capital firm specializing in life sciences and biotech investments, founded 20 years ago. With headquarters in the Netherlands, it has expanded its presence with offices in Germany and the United States, employing over 50 professionals. The firm is co-led by Managing Partner Sander Slootweg and General Partner Robbert van de Griendt. A key differentiator for Forbion is its dual-fund strategy, which pairs early-stage company creation with later-stage growth investments, enabling it to guide its portfolio companies from inception through to expansion.

Forbion invests primarily in biotech and therapeutics, focusing on innovative solutions that address high-need medical indications. The firm manages around €7.5 billion across multiple funds, including the recently announced Growth Opportunities Fund IV and Ventures Fund VIII totaling €2.3 billion. These funds primarily target Europe and North America, with investments ranging from company creation to late-stage financing. Strategic LPs include Eli Lilly, MN, and other notable institutions, reflecting confidence in Forbion's strategy and execution.

Notable portfolio companies include Azafaros - developing treatments for rare genetic diseases, VectorY - focusing on gene therapy for CNS diseases, and Genomines - a leader in metal extraction through plant-based methods. Over its history, Forbion has financed over 140 companies, including 37 built from scratch, and facilitated the approval of 21 medical products, benefitting millions of patients worldwide.